Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.

Summary

The main aim of the study is to describe plasma pharmacokinetics (PK) and pulmonary diffusion of high-dose ceftobiprole (500 mg loading dose followed by 2.5 g under continuous infusion for 24h) for mechanically-ventilated adult patients with severe community-acquired pneumonia, using population PK modelling. The secondary aims are : A- To determine whether the pharmacokinetic / pharmacodynamic (PK/PD) targets can be achieved in the plasma and epithelial lining fluid with the recommended doses of ceftobiprole. B- To define the optimal dose regimen for ceftobiprole in this population. C- To evaluate clinical recovery (at Day 3 and Day 8) and microbiological recovery (at Day 3). D- To evaluate the clinical evolution. E- To evaluate the clinical and biological tolerance.

Timeline

Start

2021-04-01

Primary completion

2023-01-04

Completion

2023-01-04

Publications

• Results Roger C, Allaouchiche B, Quintao De Moraes D, Ulrich Feudjio O, Occean BV, Friggeri A, Lefrant JY, Muller L, Breilh D. Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia. J Antimicrob Chemother. 2025 Oct 3;80(10):2644-2653. doi: 10.1093/jac/dkaf267.

Drugs

Indications